Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2920)	9/20/2013 3:46:55 PM
From: scaram(o)uche	Respond to of 3202

might interest some, haven't checked for accuracy..... twitter.com

To: scaram(o)uche who wrote (2920)	10/29/2013 6:33:08 PM
From: scaram(o)uche	Respond to of 3202

INC280 going it alone in a second HCC trial, this time a placebo controlled phase II, HCC "known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment with sorafenib or who are intolerant to sorafenib". clinicaltrials.gov Projected enrollment 69, matures 3/16. The trial that is already running..... clinicaltrials.gov but this fascinating trial is getting off to an agonizingly slow start, as are a couple of other planned 280 trials..... clinicaltrials.gov